Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod
July 19, 2019 at 18:59 PM EDT
Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.
